Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-19

FDA Approved: BEOVU — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for BEOVU (brolucizumab) from Novartis Pharmaceuticals Corporation. This action approves an expanded or updated use …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BEOVU (BROLUCIZUMAB)

Snippet

SUPPL AP for BEOVU (BROLUCIZUMAB)